Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

  • PhenoScope can cut drug development time and costs significantly, while delivering safer & more effective therapy for cancer patients
  • It can provide more precise patient dosing to reduce side effects, increase efficiency and reduce wastage

CHICAGO, IL & PALO ALTO, CA – 3 April 2024 – SimBioSys, a leading innovator in precision oncology, and General Inception (“GI”), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Read more…